Does Wegovy Make Your Face Look Older?

What actually happens to your face when you lose weight on semaglutide

Fat sits beneath the skin across the entire body, including the cheeks, temples and around the eyes. When you lose a significant amount of weight, facial fat reduces alongside fat elsewhere. For many people this is welcome, cheekbones become more defined, jawlines clearer. For others, particularly those over around 40 whose skin has less rebound elasticity, the reduction in that subcutaneous padding can leave skin looking looser or slightly sunken, which can read as age.

The key word is weight loss. Semaglutide, the active ingredient in Wegovy, produces this effect because it works. The medicine reduces appetite substantially, leading to a calorie deficit and fat loss over time. A similar effect has been documented with other routes to meaningful weight loss, bariatric surgery, very-low-calorie diets, sustained lifestyle change. The mechanism in the face is the same; the name 'Ozempic face' reflects the timing of these conversations rather than something chemically unique to the drug.

The semaglutide information page covers how the medicine works in broader clinical detail if that context helps.

Who is more likely to notice a change in facial appearance

Several factors make the facial effect more or less noticeable. Skin elasticity declines with age, so people in their fifties and sixties who lose a large amount of weight relatively quickly tend to report more visible facial change than younger people losing similar amounts. The total volume of weight lost matters too: losing 5–8% of body weight tends to affect facial appearance far less than losing 20% or more.

Rate of loss plays a role as well. Faster loss gives skin less time to contract gradually. This is partly why the titration schedule for Wegovy (starting at a low dose and increasing slowly under prescriber guidance) exists: it allows the body to adapt. People who reach higher maintenance doses and sustain them for longer typically achieve greater overall weight loss, which means a greater potential facial volume reduction.

Genetics influence how and where your body preferentially stores and loses fat. Some people carry proportionally more facial fat; they may notice a more visible change even if total weight loss is modest. There is no reliable way to predict this in advance, which is one reason honest conversations with a clinical team matter before and during treatment. You can read more about how individual results vary on the broader question of whether Wegovy makes you look older overall.

What you can do to support your skin and face during treatment

There is no clinical intervention that can fully prevent facial volume loss if you are losing significant weight, nor, for most people, would they choose one. But there are things that may help your skin stay in better condition as your weight falls.

Protein adequacy is perhaps the most consistently discussed point. Muscle and skin both need adequate protein to maintain structure; the typical recommendation during weight-loss treatment is to prioritise protein at each meal even when overall appetite has dropped substantially. Many people on semaglutide find their hunger so reduced that they are eating too little protein alongside too few calories, something a dietitian or your prescriber can help you address.

Hydration matters for skin quality in general. Strength or resistance exercise is worth mentioning too: it does not prevent facial fat loss, but maintaining muscle elsewhere in the body preserves overall body composition and general physical appearance as weight falls.

Sun protection, good sleep, and not smoking all protect collagen. None of these are specific to semaglutide, but they become more relevant when your skin is adapting to a changing body. If you are concerned about skin texture during treatment, a GP or dermatologist is the right person to speak to; your prescriber at a weight-loss service can address the weight and appetite side.

Some people exploring the broader question of how Wegovy affects appearance find it helps to understand that many of these changes (including the facial ones) tend to stabilise once weight loss slows and the body settles at a new baseline.

Is this a reason not to treat, or to treat differently?

That is the real decision most people reading this are weighing. If you are considering Wegovy and the possibility of facial volume loss feels significant, it is worth discussing the likely scale of your weight loss with a prescriber before starting. Someone losing 8% of their body weight has a very different facial-change risk profile from someone who may lose 20% or more. A prescriber can also discuss dose and titration in relation to your individual situation.

It is also worth keeping the comparison honest. Obesity carries its own effects on appearance and (far more importantly) on long-term health. The clinical trials that informed Wegovy's UK licence, including the STEP 1 trial published in the New England Journal of Medicine, enrolled tens of thousands of participants over 68 weeks. Facial appearance was not measured as an endpoint, but overall health outcomes, including cardiovascular markers, improved substantially.

If you are weighing options and want to understand whether the ageing effect is as pronounced as coverage suggests, the evidence points to it being real for some people, manageable for most, and very much dependent on individual factors that a clinical consultation can help you map. There is also a separate but related question some people raise about other physical changes during treatment that are worth understanding before starting.

Understanding the cost of treatment is a practical question too, not a superficial one. You can find context on what Wegovy typically costs in the UK and what a legitimate service includes in that price.

If you decide clinical weight-loss treatment is right for you, check your eligibility with our prescribers through a free consultation. A real clinician reads your answers the same day, your consultation goes to a GPhC-registered prescriber, not a queue. For anything else, our FAQs cover the questions we hear most often.